Orchard Therapeutics has completed the rolling submission of its Biologics License Application (BLA) to the FDA for OTL 200 (atidarsagene autotemcel), in children with early-onset metachromatic leukodystrophy (MLD).
Merck KGaA and Pfizer Inc. announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination...
Eli Lilly and Company has announced that the FDA has approved Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200),...
The CorPath 200 robotic system, from Corindus Inc, can safely assist surgeons in performing Percutaneous Coronary Interventions (PCI) while significantly...
Amgen announced that the global Phase III CodeBreaK 200 trial evaluating once daily oral Lumakras (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel